PureTech Health PLC

PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others. The Internal segment focuses on immunological, fibrotic, and lymphatic system mechanisms. The Controlled Founded Entities segment is composed of the group’s subsidiaries that are currently consolidated operational subsidiaries that either have or have plans to hire independent management teams and currently have already raised, or are currently in the process of raising, third-party dilutive capital. The Non-Controlled Founded Entities segment includes companies wherein the group no longer holds majority voting control as a shareholder and no longer has the right to elect a majority of the members of the subsidiaries’ Board of Directors. The Parent Company and Other segment represents activities that are not directly attributable to the operating segments, such as the activities of the parent, corporate support functions and certain research and development support functions that are not directly attributable to a strategic business segment as well as the elimination of intercompany transactions. The company was founded by Robert S. Langer Jr., Bennett M. Shapiro, and Daphne Zohar on May 8, 2015 and is headquartered in Boston, MA.

Nektar Therapeutics

PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF) PLC and Nektar Therapeutics (NASDAQ:NKTR) said they have mutually agreed to terminate discussions regarding a possible combination of the two companies.  The talks were first announced on 7 October 2022 in response to press speculation.

PureTech Health and Nektar Therapeutics end tie-up talks

OPENING DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Form 8 (OPD) PureTech Health PLC

PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF) PLC has confirmed that it is in talks about a possible tie-up with Nektar Therapeutics (NASDAQ:NKTR), Inc.  Responding to press speculation, PureTech said it has exchanged indicative, non-binding proposals with Nektar Therapeutics regarding a possible combination, which may include an offer for the share capital of PureTech.  “PureTech and Nektar remain in discussions regarding the proposal.

PureTech Health confirms ‘possible combination' with Nektar Therapeutics

BOSTON--(BUSINESS WIRE)--PureTech to Present at the Morgan Stanley Global Healthcare Conference

PureTech to Present at the Morgan Stanley Global Healthcare Conference

BOSTON--(BUSINESS WIRE)--PureTech Presents Data for LYT-100 Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at ERS International Congress 2022

PureTech Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Sonde Health Announces Multi-Year Partnership with Koye Pharmaceuticals

PureTech Founded Entity Sonde Health Announces Multi-Year Partnership with Koye Pharmaceuticals

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc. (“Akili”), a leading digital medicine company, today announced the start of a pivotal Phase 3 randomized, controlled study of SDT-001 (a version of AKL-T01 localized for Japanese language and culture), a product candidate designed to improve measures of attention in children diagnosed with atten

PureTech Founded Entity Akili Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Announces the Journal Lupus Publishes Investigator-Initiated Study Results

PureTech Founded Entity Akili Announces the Journal Lupus Publishes Investigator-Initiated Study Results Demonstrating Improved Executive Function in Patients with Systemic Lupus Erythematosus Following Use of AKL-T01 Product Candidate

Social Capital Suvretta Holdings Corp I

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Announces Public Company Board of Director Nominees

PureTech Founded Entity Akili Announces Public Company Board of Director Nominees

BOSTON--(BUSINESS WIRE)--PureTech Initiates Late-Stage Clinical Study of Wholly-Owned Candidate LYT-100 (Deupirfenidone) in IPF and Advances LYT-200 (Anti-Galectin-9 mAb)

PureTech Initiates Late-Stage Clinical Study of Wholly-Owned Candidate LYT-100 (Deupirfenidone) in IPF and Advances LYT-200 (Anti-Galectin-9 mAb)

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Unveils State-of-the-Art Manufacturing Facility

PureTech Founded Entity Vedanta Biosciences Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial Consortia

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, today announced the opening of a new facility designed to manufacture clinical and commercial supply for its therapeutic portfolio, including for the planned Phase 3 study and potential commercial launch of its lead candidate, VE303, in Clostridioides difficile infection. The large-scale Current Good Manufacturing P

Vedanta Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial Consortia

BOSTON--(BUSINESS WIRE)--PureTech Meets Milestone of Achieving Oral Bioavailability of Allopregnanolone in Healthy Adults Dosed with LYT-300

PureTech Meets Milestone of Achieving Oral Bioavailability of Allopregnanolone in Healthy Adults Dosed with LYT-300

BOSTON--(BUSINESS WIRE)--PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute “Long” COVID with Respiratory Complications

PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute “Long” COVID with Respiratory Complications

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that Bernat Olle, Ph.D., Chief Executive Officer of Vedanta Biosciences, will participate in a fireside chat at the JMP Securities Life Sciences Conference being held June 15-16, 2022 at the Lotte New York Palace in New York, NY. The JMP Securities Life Sciences Conference Date: Thursday, June 16, 202

Vedanta Biosciences to Participate in the JMP Securities Life Sciences Conference

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc. (“Akili”), a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, today announced that industry veteran Matt Franklin will join the company in the newly created role of President and Chief Operating Officer, effective June 21, 20

PureTech Founded Entity Akili Announces Veteran Life Sciences Executive Matt Franklin in Newly Created Role of President and Chief Operating Officer

BOSTON--(BUSINESS WIRE)--PureTech to Present at the Jefferies Healthcare Conference

PureTech to Present at the Jefferies Healthcare Conference

Roblox

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Integrates First-of-its-Kind Prescription Video Game Treatment with the Virtual World Through Partnership with Roblox

PureTech Founded Entity Akili Integrates First-of-its-Kind Prescription Video Game Treatment with the Virtual World Through Partnership with Roblox

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting

PureTech Founded Entity Vedanta Biosciences Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, today announced the details of three podium presentations of research informed by multiple clinical studies at Digestive Disease Week (DDW) 2022, being held both virtually and in person in San Diego, CA on May 21-24. The analyses cover several defined bacterial consortia candidates developed by Vedanta, and include

Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting

BOSTON--(BUSINESS WIRE)--PureTech to Present at the UBS Global Healthcare Conference

PureTech to Present at the UBS Global Healthcare Conference

BOSTON--(BUSINESS WIRE)--PureTech Presents Additional Phase 1 Data for LYT-100 at American Thoracic Society 2022

PureTech Presents Additional Phase 1 Data for LYT-100 at American Thoracic Society 2022

BOSTON--(BUSINESS WIRE)--PureTech Announces Share Buyback Program Update

PureTech Announces Share Buyback Program Update

BOSTON--(BUSINESS WIRE)--PureTech Announces Share Buyback Program of up to $50 million

PureTech Announces Share Buyback Program of up to $50 Million

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Gelesis Announces Clinical Data Demonstrating Weight Loss with GS200 in Adults with Prediabetes and T2D Presented at ECO 2022

PureTech Founded Entity Gelesis Announces Clinical Data Demonstrating Weight Loss with GS200 in Adults with Prediabetes and Type 2 Diabetes Presented at the European Congress on Obesity 2022

News for PureTech Health PLC Stock (PRTC)